Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfamide SCHEMBL28146364 | 0.90 | CA1 (0.32) | CA1 | |
| Ethanesulfonic Acid Amide SCHEMBL4974637 | 0.86 | CA1 (0.31) | CA1 | |
| Sulfamate SCHEMBL28005026 | 0.86 | CA1 (0.38) | CA1 | |
| Pyrazole SCHEMBL1829630 | 0.86 | LMNA (0.31) | — | |
| Pyrazole SCHEMBL27388414 | 0.82 | — | — | |
| Pyrazole SCHEMBL27504584 | 0.82 | — | — | |
| Pyrazole SCHEMBL31069297 | 0.82 | — | — | |
| Sulfuric Acid SCHEMBL624266 | 0.80 | CA5A (0.32) | — | |
| Sulfuric Acid SCHEMBL30034939 | 0.80 | CA5A (0.32) | — | |
| Pyrazole SCHEMBL4976449 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0946508-B1 | NITROGEN CONTAINING HETEROAROMATICS AS FACTOR Xa INHIBITORS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2009-09-23 | — | — | EP | disclosed |
| US-6903131-B2 | 3,4-di-substituted maleimide compounds as CXC chemokine receptor antagonists | SCHERING CORPORATION (US) | 2005-06-07 | — | — | US | disclosed |
| US-6878709-B2 | 3,4-di-substituted pyridazinediones as CXC chemokine receptor antagonists | SCHERING CORPORATION (US) | 2005-04-12 | — | — | US | disclosed |
| EP-1461321-A1 | 3,4-DI-SUBSTITUTED PYRIDAZINEDIONES AS CXC CHEMOKINE RECEPTOR ANTAGONISTS | Schering Corporation (US) | 2004-09-29 | — | — | EP | disclosed |
| EP-1434775-A1 | 3,4-DI-SUBSTITUTED MALEIMIDE COMPOUNDS AS CXC-CHEMOKINE RECEPTOR ANTAGONISTS | Schering Corporation (US) | 2004-07-07 | — | — | EP | disclosed |
| US-20040063709-A1 | 3,4-di-substituted pyridazinediones as CXC chemokine receptor antagonists | SCHERING CORPORATION | 2004-04-01 | — | — | US | disclosed |
| US-20040034229-A1 | 3,4-Di-substituted maleimide compounds as CXC chemokine receptor antagonists | SCHERING CORPORATION | 2004-02-19 | — | — | US | disclosed |
| WO-2003057676-A1 | 3,4-DI-SUBSTITUTED PYRIDAZINEDIONES AS CXC CHEMOKINE RECEPTOR ANTAGONISTS | SCHERING CORPORATION (US) | 2003-07-17 | — | — | WO | disclosed |
| WO-2003031440-A1 | 3,4-DI-SUBSTITUTED MALEIMIDE COMPOUNDS AS CXC-CHEMOKINE RECEPTOR ANTAGONISTS | SCHERING CORPORATION (US) | 2003-04-17 | — | — | WO | disclosed |
| US-6548512-B1 | Pyrazole derivatives such as 1-(3-amidinophenyl)-3-methyl-2-((5-(2'-aminosulfonylphenyl-1-yl)pyrimidin-2 -yl)aminocarbonyl)pyrazole; treating thromboembolic disorders | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-04-15 | — | — | US | disclosed |
| US-6020357-A | CARDIOVASCULAR DISORDERS; ANTCOAGULANTS | DUPONT PHARMACEUTICALS COMPANY (US) | 2000-02-01 | — | — | US | disclosed |
| EP-0946508-A1 | NITROGEN CONTAINING HETEROAROMATICS AS FACTOR Xa INHIBITORS | Du Pont Pharmaceuticals Company (US) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998028269-A1 | NITROGEN CONTAINING HETEROAROMATICS AS FACTOR Xa INHIBITORS | DU PONT PHARMACEUTICALS COMPANY (US) | 1998-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034229-A1 | 3,4-Di-substituted maleimide compounds as CXC chemokine receptor antagonists | CXCR1, CCR1, CCL2 | CA1 586/4885 |
| US-20040063709-A1 | 3,4-di-substituted pyridazinediones as CXC chemokine receptor antagonists | CXCR1, CCR1, ACKR3 | CA1 2050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.